Gene-editing technique to treat lung cancer is due to be tested in people in August
Chinese scientists are on the verge of being first in the world to inject people with cells modified using the CRISPR–Cas9 gene-editing technique.
A team led by Lu You, an oncologist at Sichuan University’s West China Hospital in Chengdu, plans to start testing such cells in people with lung cancer next month. The clinical trial received ethical approval from the hospital’s review board on July 6.
“It’s an exciting step forward,” says Carl June, a clinical researcher in immunotherapy at the University of Pennsylvania in Philadelphia.
There have been a number of human clinical trials using an alternative gene-editing technique, including one led by June, that have helped patients combat HIV. June is also a scientific adviser on a planned US trial that would also use CRISPR–Cas9-modified cells for the treatment of cancer.
Last month, an advisory panel of the US National Institutes of Health (NIH) approved that project. But the trial also requires a green light from the US Food and Drug Administration (FDA) and a university review board. The US researchers have said they could start their clinical trial by the end of this year.
The Chinese trial will enrol patients who have metastatic non-small cell lung cancer and for whom chemotherapy, radiation therapy and other treatments have failed. “Treatment options are very limited,” says Lu. “This technique is of great promise in bringing benefits to patients, especially the cancer patients whom we treat every day.”
The Latest on: CRISPR
via Google News
The Latest on: CRISPR
- Mitigation of off-target toxicity in CRISPR-Cas9 screens for essential non-coding elementson September 6, 2019 at 2:22 am
Pooled CRISPR-Cas9 screens are a powerful method for functionally characterizing regulatory elements in the non-coding genome, but off-target effects in these experiments have not been systematically ...
- CRISPR-Cas9-based mutagenesis frequently provokes on-target mRNA misregulationon September 6, 2019 at 2:13 am
The introduction of insertion-deletions (INDELs) by non-homologous end-joining (NHEJ) pathway underlies the mechanistic basis of CRISPR-Cas9-directed genome editing. Selective gene ablation using ...
- Cellular Computers Get a Boost With CRISPRon September 4, 2019 at 7:27 am
Cancer’s impenetrable secrets partly rely on its mysterious molecular history. As cells turn to the dark side, a whirlwind of DNA changes gradually accumulate. Like flipping multiple interlinked light ...
- A CRISPR Doyen Discusses Gene-Editing Challengeson September 4, 2019 at 5:32 am
Jennifer Doudna, winner of the 2018 Kavli Prize in Nanoscience, talks to Scientific American about what it’s like to work in perhaps the hottest research area in all of biology. She also discusses the ...
- Novel CRISPR method identifies key genes for Toxoplasma survivalon September 3, 2019 at 6:22 am
Using a new approach to genetic screening with CRISPR, researchers at the Crick have identified key genes for the survival of the parasite Toxoplasma gondii in mice. CRISPR screening is an ...
- Four U.S. CRISPR Trials Editing Human DNA to Research New Treatmentson September 3, 2019 at 5:06 am
Last fall, the birth of genetically edited twin girls in China—the world’s first “designer babies”—prompted an immediate outcry in the medical science community. The change to the twins’ genomes, ...
- University of California granted new U.S. CRISPR-Cas9 patent related to single-guide RNAon September 2, 2019 at 9:46 pm
University's 12th U.S. patent adds new compositions for CRISPR-Cas9 gene-editing technology to overall patent portfolio; expects to add five more patents in near future BERKELEY, Calif., Sept.
- CRISPR could lead to gene-editing fix for a form of male infertilityon September 1, 2019 at 4:55 am
Male mice with a mutation that prevented them producing any sperm have fathered offspring the natural way after a team in China fixed their infertility by CRISPR genome editing. The technique could ...
- Giant virus has evolved its own kind of CRISPR to destroy invaderson September 1, 2019 at 12:22 am
The mimivirus is so enormous it has its own kind of CRISPR-like immune system to defend against the smaller viruses that attack it. A team in France has confirmed how it works by transferring the ...
- BRIEF-Crispr Therapeutics AG May Offer And Sell From Time To Time Its Common Shares Having Aggregate Offering Price Of Up To $200 Millionon August 30, 2019 at 1:39 pm
Aug 30 (Reuters) - CRISPR Therapeutics AG: * CRISPR THERAPEUTICS AG - MAY OFFER AND SELL FROM TIME TO TIME ITS COMMON SHARES HAVING AGGREGATE OFFERING PRICE OF UP TO $200 MILLION * CRISPR THERAPEUTICS ...
via Bing News